Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19

Hydroxychloroquine (HCQ), also known by its trade name Plaquenil®, has been used for over 50 years as a treatment for malaria, systemic lupus erythematosus, and rheumatoid arthritis. As the COVID-19 pandemic emerged in the United States and globally in early 2020, HCQ began to garner attention as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhanel, George G., Zhanel, Michael A., Boreskie, Kevin F., Lynch, Joseph P., Karlowsky, James A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455223/
https://www.ncbi.nlm.nih.gov/pubmed/34557260
http://dx.doi.org/10.1155/2021/5942366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455223/
https://www.ncbi.nlm.nih.gov/pubmed/34557260
http://dx.doi.org/10.1155/2021/5942366

Ejemplares similares